Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication

Sanjay Rajagopalan, Jeffrey Trachtenberg, Emile Mohler, Jeffrey Olin, Scott McBride, Raphael Pak, Henrik Rasmussen, Ronald Crystal

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The long-term safety and efficacy of adenoviral delivery of growth factors in patients with peripheral arterial disease (PAD) is unknown. CI-1023 (AdGVVEGF121.10) is a replication-deficient adenovirus encoding human vascular endothelial growth factor isoform 121. In this phase I trial, we investigated the safety and efficacy of CI-1023 in subjects with advanced claudication symptoms secondary to infra-inguinal disease. Eighteen subjects >35 years of age with a median ankle brachial index (ABI) at rest of 0.525 (interquartile range 0.4) and angiographic disease involving the infra-inguinal vessels underwent intramuscular injection of CI-1023 (4 × 108 to 4 × 1010 particle units, n = 15) or placebo (n = 3). Eleven of 15 patients (73%) who received CI-1023 and 1 of 3 subjects (33%) who received placebo, completed 1 year of follow-up. Edema and rash were the most common early adverse event. One infra-inguinal bypass procedure occurred in each of the placebo and CI-1023 groups at days 29 and 104, respectively. One death (day 160) and 1 malignancy (day 274) occurred in the CI-1023 group. Conclusions on efficacy could not be made due to the small number of patients. However, there were encouraging trends in ABI at rest and peak walking time at follow-up.

Original languageEnglish
Pages (from-to)512-516
Number of pages5
JournalAmerican Journal of Cardiology
Volume90
Issue number5
DOIs
Publication statusPublished - 1 Sep 2002
Externally publishedYes

Fingerprint

Groin
Adenoviridae
Vascular Endothelial Growth Factor A
Ankle Brachial Index
Complementary DNA
Placebos
Safety
Peripheral Arterial Disease
Intramuscular Injections
Exanthema
Walking
Edema
Intercellular Signaling Peptides and Proteins
Protein Isoforms
Neoplasms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. / Rajagopalan, Sanjay; Trachtenberg, Jeffrey; Mohler, Emile; Olin, Jeffrey; McBride, Scott; Pak, Raphael; Rasmussen, Henrik; Crystal, Ronald.

In: American Journal of Cardiology, Vol. 90, No. 5, 01.09.2002, p. 512-516.

Research output: Contribution to journalArticle

Rajagopalan, Sanjay ; Trachtenberg, Jeffrey ; Mohler, Emile ; Olin, Jeffrey ; McBride, Scott ; Pak, Raphael ; Rasmussen, Henrik ; Crystal, Ronald. / Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. In: American Journal of Cardiology. 2002 ; Vol. 90, No. 5. pp. 512-516.
@article{07acac11912047bf94f1cc36b6a20fd1,
title = "Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication",
abstract = "The long-term safety and efficacy of adenoviral delivery of growth factors in patients with peripheral arterial disease (PAD) is unknown. CI-1023 (AdGVVEGF121.10) is a replication-deficient adenovirus encoding human vascular endothelial growth factor isoform 121. In this phase I trial, we investigated the safety and efficacy of CI-1023 in subjects with advanced claudication symptoms secondary to infra-inguinal disease. Eighteen subjects >35 years of age with a median ankle brachial index (ABI) at rest of 0.525 (interquartile range 0.4) and angiographic disease involving the infra-inguinal vessels underwent intramuscular injection of CI-1023 (4 × 108 to 4 × 1010 particle units, n = 15) or placebo (n = 3). Eleven of 15 patients (73{\%}) who received CI-1023 and 1 of 3 subjects (33{\%}) who received placebo, completed 1 year of follow-up. Edema and rash were the most common early adverse event. One infra-inguinal bypass procedure occurred in each of the placebo and CI-1023 groups at days 29 and 104, respectively. One death (day 160) and 1 malignancy (day 274) occurred in the CI-1023 group. Conclusions on efficacy could not be made due to the small number of patients. However, there were encouraging trends in ABI at rest and peak walking time at follow-up.",
author = "Sanjay Rajagopalan and Jeffrey Trachtenberg and Emile Mohler and Jeffrey Olin and Scott McBride and Raphael Pak and Henrik Rasmussen and Ronald Crystal",
year = "2002",
month = "9",
day = "1",
doi = "10.1016/S0002-9149(02)02524-9",
language = "English",
volume = "90",
pages = "512--516",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication

AU - Rajagopalan, Sanjay

AU - Trachtenberg, Jeffrey

AU - Mohler, Emile

AU - Olin, Jeffrey

AU - McBride, Scott

AU - Pak, Raphael

AU - Rasmussen, Henrik

AU - Crystal, Ronald

PY - 2002/9/1

Y1 - 2002/9/1

N2 - The long-term safety and efficacy of adenoviral delivery of growth factors in patients with peripheral arterial disease (PAD) is unknown. CI-1023 (AdGVVEGF121.10) is a replication-deficient adenovirus encoding human vascular endothelial growth factor isoform 121. In this phase I trial, we investigated the safety and efficacy of CI-1023 in subjects with advanced claudication symptoms secondary to infra-inguinal disease. Eighteen subjects >35 years of age with a median ankle brachial index (ABI) at rest of 0.525 (interquartile range 0.4) and angiographic disease involving the infra-inguinal vessels underwent intramuscular injection of CI-1023 (4 × 108 to 4 × 1010 particle units, n = 15) or placebo (n = 3). Eleven of 15 patients (73%) who received CI-1023 and 1 of 3 subjects (33%) who received placebo, completed 1 year of follow-up. Edema and rash were the most common early adverse event. One infra-inguinal bypass procedure occurred in each of the placebo and CI-1023 groups at days 29 and 104, respectively. One death (day 160) and 1 malignancy (day 274) occurred in the CI-1023 group. Conclusions on efficacy could not be made due to the small number of patients. However, there were encouraging trends in ABI at rest and peak walking time at follow-up.

AB - The long-term safety and efficacy of adenoviral delivery of growth factors in patients with peripheral arterial disease (PAD) is unknown. CI-1023 (AdGVVEGF121.10) is a replication-deficient adenovirus encoding human vascular endothelial growth factor isoform 121. In this phase I trial, we investigated the safety and efficacy of CI-1023 in subjects with advanced claudication symptoms secondary to infra-inguinal disease. Eighteen subjects >35 years of age with a median ankle brachial index (ABI) at rest of 0.525 (interquartile range 0.4) and angiographic disease involving the infra-inguinal vessels underwent intramuscular injection of CI-1023 (4 × 108 to 4 × 1010 particle units, n = 15) or placebo (n = 3). Eleven of 15 patients (73%) who received CI-1023 and 1 of 3 subjects (33%) who received placebo, completed 1 year of follow-up. Edema and rash were the most common early adverse event. One infra-inguinal bypass procedure occurred in each of the placebo and CI-1023 groups at days 29 and 104, respectively. One death (day 160) and 1 malignancy (day 274) occurred in the CI-1023 group. Conclusions on efficacy could not be made due to the small number of patients. However, there were encouraging trends in ABI at rest and peak walking time at follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0036710990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036710990&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(02)02524-9

DO - 10.1016/S0002-9149(02)02524-9

M3 - Article

VL - 90

SP - 512

EP - 516

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -